Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20480541 | 1.00 | LMNA (0.43) | LMNARECQLMEN1KMT2AHTT | |
| SCHEMBL1021850 | 0.87 | LMNA (0.44) | LMNARECQLMEN1KMT2AHTT | |
| SCHEMBL18342193 | 0.87 | LMNA (0.47) | LMNARECQLMEN1KMT2AHTT | |
| SCHEMBL16862549 | 0.84 | LMNA (0.42) | LMNARECQLMEN1KMT2AHTT | |
| SCHEMBL14909569 | 0.84 | ALPI (0.46) | LMNAMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL272595 | 0.84 | ALPI (0.46) | LMNAMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL14909570 | 0.84 | ALPI (0.46) | LMNAMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL18342300 | 0.82 | LMNA (0.45) | LMNARECQLMEN1KMT2AHTT | |
| SCHEMBL20974302 | 0.78 | MEN1 (0.56) | MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL20974355 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | LMNA 1971/4885RECQL 572/4885MEN1 417/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | LMNA 1971/4885RECQL 572/4885MEN1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.